Comparative Pharmacology
Head-to-head clinical analysis: ALUPENT versus SEREVENT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ALUPENT versus SEREVENT.
ALUPENT vs SEREVENT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Beta-2 adrenergic receptor agonist; relaxes bronchial smooth muscle, leading to bronchodilation.
Selective long-acting beta2-adrenergic receptor agonist; relaxes bronchial smooth muscle by increasing cyclic AMP.
Inhalation: 2 inhalations (0.65 mg per inhalation) every 3-4 hours, up to 12 inhalations per day. Oral: 20 mg three to four times daily.
50 mcg (2 inhalations) twice daily via inhalation; maximum 100 mcg/day.
None Documented
None Documented
The terminal elimination half-life of metaproterenol (Alupent) is approximately 2.5–5 hours after oral administration, and 2–4 hours after intravenous or inhaled routes. Its relatively short half-life supports dosing every 4–6 hours for bronchodilator effect.
Terminal elimination half-life of 5.5 hours (range 3–7 hours). No dose adjustment in renal or hepatic impairment; accumulation can occur in severe hepatic disease, monitor.
Renal excretion of unchanged drug and metabolites accounts for approximately 40-60% of the dose, with the remainder eliminated via biliary/fecal routes. Following oral administration, about 30-40% is recovered in urine as unchanged drug and glucuronide conjugates, and 50-60% in feces. After intravenous administration, renal elimination is 40-50% unchanged, with biliary excretion contributing 30-40%.
Primarily hepatic metabolism via CYP3A4; ~60% excreted in feces as parent drug and metabolites; ~25% in urine as metabolites; negligible (0.5%) unchanged drug in urine.
Category C
Category C
Beta-2 Adrenergic Agonist
Beta-2 Adrenergic Agonist